Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)

Status:
Completed

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Clinical trial of BAY43-9006 in patients with hepatocellular carcinoma.

Phase 3

Bayer

Niacinamide
Sorafenib